Form 4: Xeris Biopharma Director Exercises Options, Sells Shares

Xeris Biopharma Holdings, Inc. Director Jeffrey W. Sherman exercised stock options and subsequently sold a portion of the acquired shares.

Summary

• Director Jeffrey W. Sherman exercised 47,040 stock options at an exercise price of $6.66 per share on August 28, 2025.
• Following the option exercise, Mr. Sherman sold 42,232 shares of common stock at a weighted average price of $7.9209 per share on August 28, 2025.
• The sales occurred in multiple transactions with prices ranging from $7.920 to $7.935.
• After these transactions, Mr. Sherman directly holds 219,188 shares of common stock.
• An additional 5,400 shares are indirectly held through the JEFFREY W SHERMAN LIVING TRUST U/A DTD 03/21/2001.
• The exercised options were originally granted by Strongbridge Biopharma plc on October 1, 2016, assumed by Xeris Biopharma Holdings, Inc. upon its acquisition of Strongbridge, and vested fully on October 5, 2021.

Sentiment

Score: 6

Explanation: The director exercised options, indicating confidence, but also sold a significant portion of the acquired shares, which is a neutral to slightly negative signal. The net effect on direct holdings is a slight decrease from the exercised amount, but overall holdings remain substantial.

Positives

• The exercise of options indicates a director's belief in the company's long-term value, as they are converting potential future value into current shares.
• The sale price of $7.9209 per share is higher than the exercise price of $6.66, indicating a profitable transaction for the director.

Negatives

• The sale of 42,232 shares by a director could be perceived as a reduction in direct exposure to the company's stock, although a significant number of shares are still held.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale by a director might be viewed with slight caution, but the overall holdings remain substantial, and the exercise of options shows a prior commitment. The transaction itself is a routine insider disclosure.

Key Dates

Recommendation

This is a routine insider transaction where a director exercised options and then sold a portion of the acquired shares. While the sale reduces direct holdings, the director still retains a substantial stake, and the exercise itself indicates a prior positive view. Such transactions are common for compensation and liquidity purposes and typically do not signal a fundamental shift in the company's prospects. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide sufficient new information to warrant a change in investment thesis.

Keywords

Xeris Biopharma Holdings, XERS, Jeffrey W Sherman, Director, Stock Option Exercise, Insider Trading, Share Sale, Beneficial Ownership, SEC Form 4, Biopharma